Di Tomaso et al. demonstrated that both primary CSCs derived from glioblastoma (GBM) patients and their differentiated tumor counterparts express CTLA-4, with CSCs exhibiting higher expression levels [64]. This evidence concerns the gene CTLA4 and glioblastoma.